 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

GRI Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company is headquartered in La Jolla, CA.

Current Price	$6.00
Prev Close	$5.80
Open	$6.55
Dividend Yield	0.00%
50-Day Moving Average	$8.90
Beta	0.00
Avg. Volume	22,030.45
PE Ratio	-0.25

52-Week High	$36.90
52-Week Low	$5.49
Market Capitalization	$17.51M
EPS	-$23.81
Price to Book	1.15
Revenue Per Employee	N/A
Enterprise Value/EBITDA	-0.02

GRI Cohen & Steers Global Realty Majors ETF

About

Feed

Fundamentals

News